Supplemental Table 1. Association of walking intercept and slope with year 10 variables.

	Walking Int	ercept	Walking Slope		
Outcome (measured at year 10)	Estimate (SE)	P value	Estimate (SE)	P value	
Hippocampus					
Volume (cm ³)	-0.001 (0.09)	.993	-0.007 (0.09)	.938	
Mean diffusivity (10 ⁻³ mm ² /s)	-0.02 (0.02)	.306	0.01 (0.02)	.534	
Global brain measures					
GM volume (cm ³)	-0.68 (3.52)	.846	-2.37 (3.53)	.502	
GM mean diffusivity (10 ⁻³ mm ² /s)	0002 (.005)	.954	0.001 (0.005)	.750	
WM fractional anisotropy	-0.01 (0.01)	.215	0.004 (0.01)	.694	
WM radial diffusivity (10 ⁻³ mm ² /s)	0.002 (0.003)	.571	0.001 (0.003)	.734	
WM axial diffusivity (10 ⁻³ mm ² /s)	-0.002 (0.003)	.525	0.002 (0.003)	.506	
WM hyperintensities ¹	0.06 (0.47)	.900	-0.47 (0.47)	.322	
Cognition					
Modified Mini-Mental State	0.01 (0.44)	.979	-0.09 (0.44)	.830	
Examination					

Notes. Adjusted for intracranial volume (volume and mean diffusivity measures only), age, gender, race, education, and APOE ε4 carrier status. Log-transformed.

Supplemental Table 2. Comparison of the study sample to the parent HABC sample and to participants with baseline MRI only.

	Study sample	Remaining HABC	P value ¹
_	(n = 141)	sample ($n = 2934$)	
Baseline age, M (SD)	72.4 (2.4)	73.7 (2.9)	<.001
Sex, female, n (%)	84 (60%)	1422 (52%)	.08
Race, black, n (%)	59 (42%)	1080 (39%)	.60
Education, > high school, n (%)	72 (51%)	1184 (43%)	.06
Body mass index, M (SD)	27.5 (4.4)	27.4 (4.9)	.74
Cerebrovasclular disease, n (%)	7 (5%)	203 (7%)	.36
Diabetes, n (%)	12 (9%)	415 (15%)	.04
Modified mini-mental examination, <i>M</i> (SD)	92.5 (6.4)	90.3 (7.5)	<.001
Gait speed, M (SD)	1.3 (0.2)	1.2 (0.2)	<.001
Current or former smoker, n (%)	69 (49%)	1559 (57%)	
Alcohol consumption, once or more	54 (38%)	802 (29%)	.02
per week, n (%)		00= (=270)	
Walking intercept, M (SD)	3.3 (1.6)	2.8 (1.6)	<.001
Walking slope, M (SD)	-0.09 (0.11)	-0.12 (0.11)	.05
Alive at year 10	141 (100%)	2195 (75%)	n/a
	Study sample	Remaining MRI	P value ¹
<u>_</u>	(n = 141)	sample $(n = 172)$	
Baseline age, M (SD)	72.4 (2.4)	73.4 (2.9)	.002
Sex, female, n (%)	84 (60%)	95 (56%)	.63
Race, black, n (%)	59 (42%)	65 (38%)	.62
Education, > high school, n (%)	72 (51%)	87 (52%)	.90
Body mass index, M (SD)	27.5 (4.4)	27.2 (4.7)	.51
Cerebrovasclular disease, n (%)	7 (5%)	5 (3%)	.54
Diabetes, n (%)	12 (9%)	23 (14%)	.22
Modified mini-mental examination, M (SD)	92.5 (6.4)	91.9 (6.3)	.41
Gait speed, M (SD)	1.3 (0.2)	1.3 (0.3)	.58
Current or former smoker, n (%)	69 (49%)	79 (47%)	.15
Alcohol consumption, once or more	54 (38%)	47 (28%)	.05
per week, n (%)	` '	` '	
Walking intercept, M (SD)	3.3 (1.6)	3.3 (1.5)	.99
Walking slope, M (SD)	-0.09 (0.11)	-0.12 (0.11)	.15
Alive at year 13, n (%)	141 (100%)	134 (78%)	n/a

¹Determined from Welch two sample t-test for continuous measures or chi squared tests for categorical measures.

Supplemental Table 3. Descriptive statistics for self-reported time spent walking at each time point.

Time point	Mean (SD)	Median	Median assessment date
		(25 th , 75 th percentiles)	(and range)
Year 1	188.6 (447.0)	45 (0, 181.25)	December 11, 1997
			(April 28, 1997 – June 22, 1998)
Year 2	161.3 (241.9)	90 (0, 210.0)	January 21, 1999
			(February 24, 1998 – June 17, 1999
Year 3	128.3 (208.4)	60 (0, 175)	January 19, 2000
			(July 6, 1999 – September 25, 2000)
Year 4	135.9 (382.4)	60 (0, 142.5)	January 2, 2001
			(July 5, 2000 – December 8, 2001)
Year 5	116.7 (179.0)	60 (0, 140.0)	December 14, 2001
			(June 20, 2001 – June 20, 2002)
Year 6	78.7 (127.1)	30 (0, 120.0)	November 21, 2002
			(June 5, 2002 – May 20, 2003)
Year 7	103.7 (281.2)	30 (0, 116.0)	November 12, 2003
			(May 1, 2003 – June 4, 2004)
Year 8	97.0 (184.8)	30 (0, 140.0)	January 20, 2005
			(July 30, 2004 – May 31, 2005)
Year 9	117.8 (207.4)	40 (0, 120.0)	December 13, 2005
			(July 11, 2005 – May 2, 2006)
Year 10	86.1 (121.2)	45 (0, 105.0)	November 21, 2006
			(June 7, 2006 – June 5, 2007)

Supplement Table 4. Correlation of Walking Intercept and Slope Scores with Sample Characteristics.

	Walking Intercept	Walking Slope
Demographics		
Age	.17*	11
Sex, female	.03	05
Race, black	12	04
Education	.13	07
Body mass index	07	.04
Chronic disease conditions at first MRI		
Cardiovascular disease	.01	10
Stroke	.05	13
Diabetes	05	03
APOE ε4 carrier	19**	.11
Gait speed at first MRI	.05	.21*
Health behavior at first MRI		
Current or former smoker	.01	.05
Current or former alcohol drinker	.03	.11
Systolic blood pressure at first MRI	12	005
Use of medications for hypertension	05	06

Notes. For continuous variables, Pearson correlations were calculated; for categorical variables, Kendall correlations were calculated. *p < .05; *** p < .01

Supplemental Table 5. Summary of primary analyses with individuals with chronic stroke excluded

	Adjusted fo	r demogra	aphic factors an	d genetic	Further ad	justed for	physical heal	th at year
	r	isk for cog	gnitive decline ¹			10^2		
	Walking In	tercept	Walking	Slope	Walking Ir	ntercept	Walkin	g Slope
	Estimate		Estimate		Estimate		Estimate	
Outcome	(SE)	P value	(SE)	P value	(SE)	P value	(SE)	P value
Hippocampus								
Volume (cm ³)	0.09 (0.08)	.256	0.19 (0.08)	.016	0.03 (0.09)	.745	0.21 (0.09)	.017
Mean diffusivity	.008 (.009)	.357	005 (.009)	.570	.007 (.009)	.414	005	.524
$(10^{-3} \text{ mm}^2/\text{s})$							(.009)	
Global brain measures								
GM volume (cm ³)	0.18 (2.24)	.934	4.85 (2.19)	.027	0.57 (2.39)	.810	6.49 (2.32)	.005
GM mean diffusivity	.001 (.003)	.632	008 (0.003)	.006	.002 (.003)	.425	005	.090
$(10^{-3} \text{ mm}^2/\text{s})$							(.003)	
WM fractional	.006 (.006)	.385	.005 (.006)	.463	.003 (.006)	.655	.004 (.006)	.535
anisotropy								
WM radial diffusivity	.0002 (.002)	.869	004 (.002)	.009	.0004 (.002)	.833	004	.038
$(10^{-3} \text{ mm}^2/\text{s})$							(.002)	
WM axial diffusivity	.003 (.002)	.224	007 (.002)	<.001	.003 (.002)	.265	006	.006
$(10^{-3} \text{ mm}^2/\text{s})$							(.002)	
WM hyperintensities ³	0.37 (0.30)	.209	0.20 (0.29)	.504	0.28 (0.31)	.368	0.36 (0.30)	.237
Cognition								

 Δ Modified Mini-Mental 0.30 (0.39) .439 1.05 (0.37) .004 0.35 (0.44) .432 1.07 (0.41) .009 State Examination

¹Adjusted for intracranial volume (volumetric and mean diffusivity measures only), age, gender, race, education, and APOE ε4 carrier status.

²Further adjusted for body mass index, gait speed, chronic disease conditions (diabetes, stroke, cardiovascular disease), health behaviours (smoking and drinking status), systolic blood pressure, and use of hypertensive medications.

GM = gray matter. WM = white matter.

³Log-transformed

Supplemental Table 6. Association of year 10 walking score (log-transformed) with structural MRI variables

Outcome	Estimate (SE)	P value	
Hippocampus			
Δ Volume (cm ³)	0.11 (0.07)	.142	
Δ Mean diffusivity (10 ⁻³ mm ² /s)	.003 (.008)	.694	
Global brain measures			
Δ GM volume (cm ³)	0.39 (2.08)	.850	
Δ GM mean diffusivity (10^{-3} mm ² /s)	004 (.003)	.132	
Δ WM fractional anisotropy	.013 (.006)	.018	
Δ WM radial diffusivity	-0.003 (.002)	.071	
$(10^{-3} \text{ mm}^2/\text{s})$			
Δ WM axial diffusivity (10 ⁻³ mm ² /s)	-0.001 (0.002)	.765	
Δ WM hyperintensities	0.56 (0.30)	.065	
Cognition			
Δ Modified Mini-Mental State Examination	0.34 (0.34)	.318	

Notes. Adjusted for intracranial volume (volumetric and mean diffusivity measures only), age, gender, race, education, and APOE ε4 carrier status.

Supplemental Table 7. Association of walking slope from year 6 to year 10 with changes in outcome variables between year 10 and year 13.

	Walking Slope			
Outcome (measured at year 10)	Estimate (SE)	P value		
Нірросатриѕ				
Δ Volume (cm ³)	0.07 (0.10)	.518		
Δ Mean diffusivity ($10^{-3} \text{ mm}^2/\text{s}$)	0.004 (0.01)	.750		
Global brain measures				
Δ GM volume (cm ³)	3.03 (2.94)	.303		
Δ GM mean diffusivity (10 ⁻³ mm ² /s)	-0.008 (0.004)	.031		
Δ WM fractional anisotropy	0.02 (0.01)	.028		
Δ WM radial diffusivity (10 ⁻³ mm ² /s)	-0.003 (0.002)	.146		
Δ WM axial diffusivity (10 ⁻³ mm ² /s)	-0.003 (0.003)	.327		
Δ WM hyperintensities ¹	-0.43 (0.44)	.328		
Cognition				
Δ Modified Mini-Mental State Examination	0.17 (0.50)	.729		

Notes. Adjusted for intracranial volume (volume and mean diffusivity measures only), age, gender, race, education, APOE ε4 carrier status, and walking intercept.

Log-transformed.

Supplemental Table 8. Association of 400-meter walk performance with changes in outcome variables between year 10 and year 13.

	Predictor				
	400 Meter Intercept		400 Meter Slope		
Outcome	Estimate (SE)	P value	Estimate (SE)	P value	
Hippocampus					
Δ Volume (cm ³)	-0.06 (0.09)	.472	-0.10 (0.08)	.230	
Δ Mean diffusivity	-0.02 (0.01)	.084	-0.01 (0.01)	.110	
$(10^{-3} \text{ mm}^2/\text{s})$					
Global brain measures					
Δ GM volume (cm ³)	-2.23 (2.39)	.350	-2.21 (2.31)	.339	
Δ GM mean diffusivity	-0.002 (0.003)	.546	0.001 (0.003)	.691	
Δ WM fractional anisotropy	0.005 (0.006)	.429	-0.010 (0.006)	.102	
Δ WM radial diffusivity	-0.002 (0.002)	.301	0.002 (0.002)	.240	
$(10^{-3} \text{ mm}^2/\text{s})$					
Δ WM axial diffusivity	-0.002 (0.002)	.273	0.003 (0.002)	.224	
$(10^{-3} \text{ mm}^2/\text{s})$					
Δ WM hyperintensities	-0.28 (0.35)	.428	-0.17 (0.34)	.613	
Cognition					
Δ Modified Mini-Mental	0.01 (0.41)	.978	-0.03 (0.37)	.937	
State Examination					

Notes: Time to walk 400 meters was assessed at years 1, 2, 4, 6, 8, and 10. Higher scores indicate poorer physical performance. Thus, a positive slope would indicate a worsening in performance over 10 years. The correlation between the time spent walking slope and the 400-meter walk slope was modest (r = -.13).

Estimates are adjusted for intracranial volume (volumetric and mean diffusivity measures only), age, gender, race, education, and APOE ϵ 4 carrier status.